The efficacy of a 7-day switch therapy with parenteral cefuroxime in a dose of 750 mg for 3-5 days followed by the use of oral cefuroxime axetil in a dose of 500 mg every 12 hours was compared with that of a 7-day therapy with parenteral cefuroxime in a dose of 750 mg every 8 hours in hospitalized patients with community-acquired pneumonia. The clinical and bacteriological efficacies and pharmacokinetic properties of both the dosage forms were estimated. It was shown that the clinical and bacteriological effects did not significantly differ in the patients under the parenteral regimen with cefuroxime and under the parenteral-to-oral regimen with cefuroxime and cefuroxime axetil: the cure in 75 and 83 per cent of the patients and the bacteriological response in 100 and 86 per cent of the cases respectively. The results indicated that the cost of the switch therapy was much lower while the efficacy did not decrease.
Download full-text PDF |
Source |
---|
Naunyn Schmiedebergs Arch Pharmacol
January 2025
Hannover Medical School, Institute of Pharmacology, D-30625, Hannover, Germany.
J Infect Dev Ctries
September 2024
Division of Allergy and Immunology, Department of Pediatrics; School of Medicine, University of Kyrenia, Kyrenia, Cyprus.
Pharmaceutics
October 2024
LAQV-REQUIMTE, Department of Chemistry, NOVA School of Science and Technology, NOVA University of Lisbon, 2819-516 Caparica, Portugal.
Low oral bioavailability is a common feature in most drugs, including antibiotics, due to low solubility in physiological media and inadequate cell permeability, which may limit their efficacy or restrict their administration in a clinical setting. Cefuroxime is usually administered in its prodrug form, cefuroxime axetil. However, its preparation requires further reaction steps and additional metabolic pathways to be converted into its active form.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
October 2024
Institute of Pharmacology, Hannover Medical School, Hannover, D-30625, Germany.
Rising bacterial resistance is a global threat, causing rising financial burdens on healthcare systems and endangering effective treatment of bacterial infections. To ensure the efficacy of antibacterial drugs, it is essential to identify the most dangerous pathogens and vulnerable antibacterial drugs. Previous research by our group suggested irrational outpatient prescribing practices in Germany, supporting a growing bacterial resistance.
View Article and Find Full Text PDFNaunyn Schmiedebergs Arch Pharmacol
September 2024
Institute of Pharmacology, Hannover Medical School, 30625, Hannover, Germany.
Previous research from our group revealed a strong association between daily defined dose (DDD)-costs and -prescriptions of antibacterial drugs in Germany ( https://pubmed.ncbi.nlm.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!